JDRF announces ProSciento as the first ever California wide sponsor of the Northern California and Southern California One Walks. ProSciento, a leading clinical research organization headquartered in Chula Vista, California, has been a longtime JDRF supporter. Since 2007, they have participated in the JDRF San Diego Gala, TypeOneNation Summit, and the One Walk, contributing over $100,000 from fundraising and sponsorship to support Type 1 Diabetes (T1D) research. ProSciento is committed to Creating a World Without T1D.
“ProSciento is delighted to announce our California-wide partnership with JDRF! ProSciento is proud to be the first ever state-wide One Walk sponsor! This expanded partnership personifies our core value through the genuine desire to make a positive difference in our community through science and to support others in metabolic research. Thank you, JDRF for establishing a platform for us to connect with our community,” a spokesperson said.
Each year, the JDRF One Walks in Northern and Southern California bring together over 10,000 walkers to change the future of T1D. Many of these walkers have T1D themselves, and many more are friends, family, or coworkers of someone challenged by this disease and who walk with the common goal of better treating, preventing, and ultimately curing T1D, a life-threatening disease that affects over 1.6 million Americans.
This year the Northern and Southern California One Walks will take place on Sunday, November 7th – Your Place, Your Pace, Your Way! It is an opportunity for JDRF walkers throughout California to gather with their family and friends to celebrate their loved one(s) living with T1D and the fundraising efforts that they have made to accelerate T1D research.
To join JDRF and ProSciento for a One Walk in Northern or Southern California, please click on the walk closest to your location:
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for type 1 and type 2 diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
Learn more about ProSciento’s Type 1 Diabetes studies here: https://bit.ly/3CtsVnm